دورية أكاديمية
Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
| العنوان: | Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab. |
|---|---|
| المؤلفون: | Ho TC; John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, U.S.A., Maamari RN; John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, U.S.A., Kossler AL; Department of Ophthalmology, Byers Eye Institute, Palo Alto, California, U.S.A., Sears CM; Department of Ophthalmology, Byers Eye Institute, Palo Alto, California, U.S.A., Freitag SK; Department of Ophthalmology, Ophthalmic Plastic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, U.S.A., Reshef ER; Department of Ophthalmology, Ophthalmic Plastic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, U.S.A., Shinder R; Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York, U.S.A., Rootman DB; Division of Orbital and Ophthalmic Plastic Surgery, Jules Stein Eye Institute, University of California, Los Angeles, California, U.S.A., Diniz SB; Division of Orbital and Ophthalmic Plastic Surgery, Jules Stein Eye Institute, University of California, Los Angeles, California, U.S.A., Kahana A; Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, U.S.A.; Kahana Oculoplastic & Orbital Surgery, Rochester, Michigan, U.S.A., Schlachter D; Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, U.S.A., Do TH; Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, U.S.A., Kally P; Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, U.S.A., Turner S; Kahana Oculoplastic & Orbital Surgery, Rochester, Michigan, U.S.A., Mokhtarzadeh A; Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, U.S.A., Harrison AR; Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, U.S.A., Hwang CJ; Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, U.S.A., Kim HJ; Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, U.S.A., Avila SA; Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, U.S.A., Thomas DA; Department of Ophthalmology, Georgia Regents University, Augusta, Georgia, U.S.A., Magazin M; Department of Ophthalmology, Georgia Regents University, Augusta, Georgia, U.S.A., Wester ST; Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida, U.S.A., Lee WW; Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida, U.S.A., Clauss KD; Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida, U.S.A., Holds JB; Ophthalmic Plastic and Cosmetic Surgery Inc., Des Peres, Missouri, U.S.A.; Departments of Ophthalmology and Otolaryngology-Head and Neck Surgery, Saint Louis University, St. Louis, Missouri, U.S.A., Sniegowski M; Department of Ophthalmology, University of Missouri Kansas City, Kansas City, Missouri, U.S.A., Compton CJ; Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, Kentucky, U.S.A., Briggs C; Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, Kentucky, U.S.A., Malik AI; Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas, U.S.A., Lucarelli MJ; Oculoplastic, Facial Cosmetic & Orbital Surgery, Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, U.S.A., Burkat CN; Oculoplastic, Facial Cosmetic & Orbital Surgery, Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, U.S.A., Patel LG; Retina Center of Texas, Dallas, Texas, U.S.A., Couch SM; John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, U.S.A. |
| المصدر: | Ophthalmic plastic and reconstructive surgery [Ophthalmic Plast Reconstr Surg] 2023 Mar-Apr 01; Vol. 39 (2), pp. 150-155. Date of Electronic Publication: 2022 Sep 09. |
| نوع المنشور: | Observational Study; Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins for the American Society of Ophthalmic Plastic and Reconstructive Surgery Country of Publication: United States NLM ID: 8508431 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-2677 (Electronic) Linking ISSN: 07409303 NLM ISO Abbreviation: Ophthalmic Plast Reconstr Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 199 - : Hagerstown, MD : Lippincott Williams & Wilkins for the American Society of Ophthalmic Plastic and Reconstructive Surgery Original Publication: [New York, NY : Raven Press Publishers], c1985- |
| مواضيع طبية MeSH: | Graves Ophthalmopathy*/drug therapy , COVID-19* , Exophthalmos*, Humans ; Female ; Middle Aged ; Male ; Cross-Sectional Studies |
| مستخلص: | Purpose: In response to the coronavirus (COVID-19) pandemic, teprotumumab production was temporarily halted with resources diverted toward vaccine production. Many patients who initiated treatment with teprotumumab for thyroid eye disease were forced to deviate from the standard protocol. This study investigates the response of teprotumumab when patients receive fewer than the standard 8-dose regimen. Methods: This observational cross-sectional cohort study included patients from 15 institutions with active or minimal to no clinical activity thyroid eye disease treated with the standard teprotumumab infusion protocol. Patients were included if they had completed at least 1 teprotumumab infusion and had not yet completed all 8 planned infusions. Data were collected before teprotumumab initiation, within 3 weeks of last dose before interruption, and at the visit before teprotumumab reinitiation. The primary outcome measure was reduction in proptosis more than 2 mm. Secondary outcome measures included change in clinical activity score (CAS), extraocular motility restriction, margin reflex distance-1 (MRD1), and reported adverse events. Results: The study included 74 patients. Mean age was 57.8 years, and 77% were female. There were 62 active and 12 minimal to no clinical activity patients. Patients completed an average of 4.2 teprotumumab infusions before interruption. A significant mean reduction in proptosis (-2.9 mm in active and -2.8 mm in minimal to no clinical activity patients, P < 0.01) was noted and maintained during interruption. For active patients, a 3.4-point reduction in CAS ( P < 0.01) and reduction in ocular motility restriction ( P < 0.01) were maintained during interruption. Conclusions: Patients partially treated with teprotumumab achieve significant reduction in proptosis, CAS, and extraocular muscle restriction and maintain these improvements through the period of interruption. Competing Interests: The following authors are consultant/advisor for Horizon: Christopher Compton, Suzanne Freitag, Andrew Harrison, John Holds, Andrea Kossler, Wendy Lee, Amina I Malik, Daniel Rootman, Sara Wester, Dianne Schlachter, Roman Shindler, Matthew Sniegowski. Suzanne Freitag: Poriferous LLC—consultant/advisor; WL Gore and Associates—consultant/advisor. Andrew Harrison: RVL Pharmaceuticals—consultant/advisor. John Holds: Revance Therapeutics—ownership interests; Cypris Medical—ownership interests. Alan Kahana: Stryker Corporation—consultant/advisor, BioTissue Inc.—consultant/advisor; Genentech, Inc Researcher. Andrea Kossler: RVL pharmaceuticals—consultant/advisor; Axogen Inc—consultant/advisor; Immunovant Inc—consultant/advisor. Wendy Lee: Allergan—consultant/advisor, Galderma—consultant/advisor, Revance—consultant/advisor, RVL pharmaceuticals—consultant/advisor, Mallinckrodt Pharmaceuticals—consultant/advisor, Evolus—consultant/advisor; RoC—consultant/advisor; Osmotica—consultant/advisor. Daniel Rootman: Celularity—consultant/advisor. The other authors authors have no financial or conflicts of interest to disclose. (Copyright © 2022 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.) |
| References: | N Engl J Med. 2017 May 4;376(18):1748-1761. (PMID: 28467880) Am J Ophthalmol Case Rep. 2020 May 15;19:100744. (PMID: 32462101) Ophthalmology. 2021 Nov;128(11):1627-1651. (PMID: 33930408) N Engl J Med. 2020 Jan 23;382(4):341-352. (PMID: 31971679) Ophthalmology. 2007 Mar;114(3):621-2; author reply 622. (PMID: 17324709) Ophthalmic Plast Reconstr Surg. 2002 Jan;18(1):11-7. (PMID: 11910320) Ophthalmic Plast Reconstr Surg. 1993 Jun;9(2):77-82. (PMID: 8323911) Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. (PMID: 33865501) J Manag Care Pharm. 2013 Nov-Dec;19(9):783-8. (PMID: 24156647) Orbit. 2022 Oct;41(5):539-546. (PMID: 34060414) PLoS One. 2019 May 3;14(5):e0215837. (PMID: 31050671) Mayo Clin Proc. 2014 Mar;89(3):361-73. (PMID: 24582195) Ophthalmology. 2022 Apr;129(4):438-449. (PMID: 34688699) Ophthalmic Plast Reconstr Surg. 2021 Nov-Dec 01;37(6):583-591. (PMID: 33710036) Clin Pharmacokinet. 2021 Aug;60(8):1029-1040. (PMID: 33768488) Eye (Lond). 2022 Aug;36(8):1553-1559. (PMID: 34244669) Ophthalmology. 1981 Jun;88(6):499-506. (PMID: 7022304) P T. 2011 Nov;36(11):740-57. (PMID: 22346307) Clin Endocrinol (Oxf). 1997 Jul;47(1):9-14. (PMID: 9302365) N Engl J Med. 2010 Feb 25;362(8):726-38. (PMID: 20181974) Surv Ophthalmol. 2013 Jan-Feb;58(1):63-76. (PMID: 23217588) J Neuroophthalmol. 2021 Dec 1;41(4):461-468. (PMID: 33417417) Eye (Lond). 2021 Sep;35(9):2607-2612. (PMID: 33221815) |
| معلومات مُعتمدة: | P30 EY026877 United States EY NEI NIH HHS |
| المشرفين على المادة: | Y64GQ0KC0A (teprotumumab) |
| تواريخ الأحداث: | Date Created: 20220912 Date Completed: 20230307 Latest Revision: 20240109 |
| رمز التحديث: | 20240109 |
| مُعرف محوري في PubMed: | PMC10771969 |
| DOI: | 10.1097/IOP.0000000000002267 |
| PMID: | 36095848 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-2677 |
|---|---|
| DOI: | 10.1097/IOP.0000000000002267 |